drugset / Trial / NCT07523321

Dexmedetomidine-esketamine Combination and Moderate-to-severe Pain After Spinal Surgery

NCT07523321

Phase 4 Not yet recruiting 274 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Spinal surgery is generally followed by severe postoperative pain, and poor pain control may cause adverse outcomes such as cardiovascular events, neurocognitive disorders, and chronic postsurgical pain (CPSP). In previous studies, perioperative use of dexmedetomidine or esketamine is each associated with improved analgesia after surgery. Recent studies suggest that combined use of dexmedetomidine and esketamine may produce synergetic effects in improving analgesia. This trial is designed to test the hypothesis that perioperative combined use of dexmedetomidine and esketamine may improve analgesia and reduce moderate-to-severe pain in patients after spinal surgery.

Timeline

Start
2026-04
Primary completion
2027-04
Completion
2027-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.2 ug/kg Intravenous
Subject Dexmedetomidine Other / unclassified 1.5 ug/ml Intravenous
Subject Dexmedetomidine Other / unclassified 1.5 ug Intravenous
Subject Dexmedetomidine Other / unclassified 3 ug Intravenous
Subject Esketamine Other / unclassified 0.1 mg/kg Intravenous
Subject Esketamine Other / unclassified 0.5 mg/ml Intravenous
Subject Esketamine Other / unclassified 0.5 mg Intravenous
Subject Esketamine Other / unclassified 1 mg Intravenous
Background Sufentanil Other / unclassified 1.25 ug/ml Intravenous
Background Sufentanil Other / unclassified 1.25 ug Intravenous
Background Sufentanil Other / unclassified 2.5 ug Intravenous

Indications

No indication recorded.